Grufity logo
Grufity logo
SRZN

SRZN - Surrozen, Inc. Stock Price, Fair Value and News

$22.67-0.47 (-2.03%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

2/100

SRZN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

2/100

SRZN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SRZN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SRZN Price Action

Last 7 days

12.0%

Last 30 days

-17.7%

Last 90 days

-9.5%

Trailing 12 Months

144.4%

SRZN RSI Chart

SRZN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SRZN Valuation

Market Cap

265.9M

Price/Earnings (Trailing)

-0.78

Price/Sales (Trailing)

35.48

EV/EBITDA

-0.65

Price/Free Cashflow

-7.91

SRZN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SRZN Fundamentals

SRZN Revenue

Revenue (TTM)

7.5M

Rev. Growth (Yr)

408.65%

Rev. Growth (Qtr)

846.97%

SRZN Earnings

Earnings (TTM)

-342.5M

Earnings Growth (Yr)

-372.75%

Earnings Growth (Qtr)

30.38%

SRZN Profitability

EBT Margin

-3229.62%

Return on Equity

123.15%

Return on Assets

-283.77%

Free Cashflow Yield

-12.65%

SRZN Investor Care

Shares Dilution (1Y)

35.26%

Diluted EPS (TTM)

-38.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20267.5M---
20258.9M7.1M5.3M3.5M
2024--11.6M10.7M
2022---12.5M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Surrozen, Inc.

SRZN
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
 CEO
 WEBSITEsurrozen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES74

Surrozen, Inc. Frequently Asked Questions

SRZN is the stock ticker symbol of Surrozen, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Surrozen, Inc. is 265.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, SRZN's PE ratio (Price to Earnings) is -0.78 and Price to Sales (PS) ratio is 35.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRZN PE ratio will change depending on the future growth rate expectations of investors.